Skip to main content
Maura Dickler, MD, Oncology, New York, NY

Maura N Dickler MD


Associate Professor, Medicine, Weill Cornell Medical College

Join to View Full Profile
  • 205 E 64th StNew York, NY 10021

  • Phone+1 212-639-2000

  • Fax+1 212-794-5847

Are you Dr. Dickler?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Maura Dickler, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York, Illinois, and Illinois. She is an Associate Professor at Weill Cornell Medical College.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1991 - 1994
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1991

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1995 - 2026
  • IL State Medical License
    IL State Medical License 1991 - 1996
  • IL State Medical License
    IL State Medical License 1991 - 1996
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Authored Content

  • A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced PeripheralAugust 2018

Press Mentions

  • NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an Individual
    NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an IndividualDecember 10th, 2020
  • Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology
    Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly OncologyDecember 3rd, 2020
  • FDA ODAC Votes on Safety and Efficacy of Ramucirumab plus Erlotinib for EGFR+ NSCLC
    FDA ODAC Votes on Safety and Efficacy of Ramucirumab plus Erlotinib for EGFR+ NSCLCFebruary 27th, 2020
  • Join now to see all